Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal

AM1710 (3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo(c) chromen-6-one), a cannabilactone cannabinoid receptor 2 (CB2) agonist, suppresses chemotherapy-induced neuropathic pain in rodents without producing tolerance or unwanted side effects associated with CB1 receptors; however, the signaling p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Pharmacol
Päätekijät: Li, Ai-Ling, Lin, Xiaoyan, Dhopeshwarkar, Amey S., Thomaz, Ana Carla, Carey, Lawrence M., Liu, Yingpeng, Nikas, Spyros P., Makriyannis, Alexandros, Mackie, Ken, Hohmann, Andrea G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: The American Society for Pharmacology and Experimental Therapeutics 2019
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6324648/
https://ncbi.nlm.nih.gov/pubmed/30504240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.118.113233
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia